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ABSTRACT
Background: In this retrospective analysis, we explored the prognostic and 
predictive value of the systemic immune-inflammation index (SII), based on 
lymphocyte, neutrophil, and platelet counts, at baseline and changes at week 6 during 
first-line sunitinib in patients with metastatic renal cell cancer (RCC).
Results: Patients were stratified into high SII (≥ 730) and low SII (< 730) 
groups. SII was associated with objective response, p < 0.0001. The median PFS 
was 6.3 months (95% CI 5.5–8.9) in patients with SII ≥ 730 and 18.7 months (95% 
CI 14.7–22.8) in those with SII < 730, p < 0.0001. The median OS was 43.6 months 
(95% CI 35.3–52.1) in patients with SII < 730, and 13.5 months (95% CI 9.8–18.5) 
in those with SII ≥ 730, p < 0.0001. In multivariate analysis, performance status, 
IMDC score and SII were able to predict OS (HR = 3.29, HR = 1.71 and HR = 1.79, 
respectively). 
Materials and Methods: We included 335 consecutive RCC patients treated with 
first-line sunitinib. The X-tile 3.6.1 software (Yale University, New Haven, CT) was 
used for bioinformatic analysis of the data to determine the cutoff value of SII. 
Progression-free survival (PFS), overall survival (OS) and their 95% confidence 
interval (95% CI) were estimated by Kaplan-Meier method and compared with 
logrank test. The impact of SII conversion at week 6 of treatment on PFS and OS 
was evaluated by Cox regression analyses.
Conclusions: The SII and its changes during treatment represent a powerful 
prognostic indicator of clinical outcome in patients with metastatic RCC. 
Oncotarget2www.impactjournals.com/oncotarget
INTRODUCTION
Renal cell carcinoma (RCC) is the most common 
type of kidney cancer in adults and about 30% of patient 
with diagnosis of kidney cancer develop metastatic 
disease [1]. A predominant role in kidney cancer is 
played by inactivation of Von Hippen Lindau (VHL) 
tumor suppressor gene with consequent increased cellular 
amount of Hypoxia-Inducible Factor-1 alpha (HIF-1a) 
that cause abnormal cellular growth and angiogenesis 
[2–4]. Therefore inhibition of angiogenesis represents 
the mainstay of treatment of metastatic RCC [5, 6]. 
Many evidences about the role of host inflammatory 
response in carcinogenesis and disease progression of 
many cancers have recently emerged. Proinflammatory 
cytokines but also immune-inflammatory circulating cells 
(neutrophils, lymphocytes and platelets) seem to play a 
role in promoting cancer cell proliferation and invasion 
[7]. In this scenario inflammatory circulating cells has 
been recently evaluated and associated with prognosis in 
several cancers including RCC [8–13]. 
A new inflammatory index, the systemic immune 
inflammation index (SII), based on neutrophil, lymphocyte 
and platelet counts has been recently found to be associated 
with poor outcome in patients with hepatocellular 
carcinoma [14]. The rationale of this new index is based on 
the combination of three factors independently related to 
prognosis in some cancers. This combination was thought 
to have a stronger prognostic power.
In this retrospective analysis, we aimed to evaluate 
prognostic implications of SII at baseline and changes at 
week 6 during first-line sunitinib in patients with mRCC.
RESULTS
Patients
A total of 335 patients with a median age of 
63 years (range, 27 to 88 years) who were diagnosed 
with unresectable or metastatic RCC and underwent first-
line treatment with sunitinib were included in the study. 
Histotype clear cell carcinoma was reported in 94% of 
cases; among all patients 35%, 52.5% and 12.5% were 
classified in the favorable, intermediate and poor prognostic 
groups according to the “International Metastatic Renal 
Cell Carcinoma Database Consortium (IMDC) model”, 
respectively. Baseline characteristics of patients are shown 
in Table 1. An optimal cutoff point for the SII of 730 × 109 
stratified these patients into high (≥ 730) and low SII 
(< 730) groups. Among the study population, 209 and 126 
had low and high SII values, respectively.
SII and objective response
An objective tumor response was reported in 115 
of 321 evaluable patients (35.8%), including complete 
response (CR, n = 13, 4.0%) and partial response (PR, 
n = 102, 31.8%), respectively; stable disease (SD) was 
reported in 141 cases (43.9%) and progressive disease 
(PD) in 65 (20.1%), whereas in the remaining 14 cases 
(4.2%) the objective response was not evaluated, mainly 
due to early clinical deterioration. An association was 
observed between baseline SII < 730 or ≥ 730 and either 
objective response (CR+PR vs SD+PD), p < 0.0001, or 
clinical benefit (CR*PR*SD vs PD), p < 0.0001, and 
between 6-week SII < 730 or ≥ 730 and either objective 
response (CR+PR vs SD+PD), p < 0.0001, or clinical 
benefit (CR*PR*SD vs PD), p < 0.0001.
Grade 3–4 toxicities occurred in 162 of 335 (48.4%) 
patients. Grade 3–4 neutropenia was reported in 24 (7.5%) 
patients, grade 3–4 thrombocytopenia in 26 (7.8%) and 
grade 3–4 anaemia in 17 (5%). No correlation between 
baseline and week-6 SII and grade 3–4 toxicities was 
found.
SII and survival 
The median follow-up was 49 months (range 1 to 
102). At the time of analysis, 260 of the 335 (77.6%) 
patients had progressed and 193 (57.6%) died. The median 
progression-free survival (PFS) was 14.2 months (95% 
confidence interval (CI) 12.1–17.2) and the median overall 
survival (OS) was 32.7 months (95% CI 27.1–36.4). The 
median PFS was 6.3 months (95% CI 5.5–8.9) in patients 
with baseline SII ≥ 730 and 18.7 months (95% CI 14.7–
22.8) in those with SII < 730, p < 0.0001 (Figure 1A). 
The median OS was 43.6 months (95% CI 35.3-52.1) in 
patients with baseline SII < 730, and 13.5 months (95% 
CI 9.8–18.5) in those with baseline SII ≥ 730, p < 0.0001 
(Figure 1B). 
A univariate analysis revealed that ECOG 
performance status, IMDC score and baseline SII 
were significant predictors of PFS and OS (Table 2). In 
multivariate analysis, ECOG performance status and 
SII at baseline remained significant predictors of PFS 
(HR = 3.29, 95% CI 2.13–5.07, p < 0.0001; HR = 1.71, 
95% CI 1.33–2.21, p < 0.0001) and of OS (HR = 3.34, 
95% CI 2.10–5.23, p < 0.0001; HR = 1.84, 95% CI 
1.35–2.50, p < 0.0003); whereas IMDC score (poor and 
intermediate vs good risk)s howed a borderline ability to 
predict PFS (HR = 1.32, 95% CI 0.99–1.76, p = 0.058), 
and remained as predictor of OS only (HR = 1.79, 95% CI 
1.25–2.55, p = 0.001) 
Changes in SII at week 6 and clinical outcome 
We divided the two baseline SII groups (SII < 730 
or ≥ 730) on the basis of the week 6 SII (< 730 or ≥ 730), 
obtaining 4 subgroups: 1) low-low (baseline SII < 730 and 
week 6 SII < 730); low-high (baseline SII < 730 and week 
6 SII ≥ 730); high–low (baseline SII ≥ 730 and week 6 SII 
< 730); and high–high (baseline SII ≥ 730 and week 6 SII 
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≥ 730). Patients with high baseline SII that remained ≥ 730 
at week 6 (high-high SII group) had a poor prognosis with 
a median PFS of 4 months (95% CI 2.6–5.8) and a median 
OS of 9.4 months (95% CI 6.1–13.5). Patients with 
high-low SII group had a median PFS of 9.2 mo (95% 
CI 6.2–10.6) and a median OS of 18.2 months (95% CI 
13.1–27.1). The low-high SII group was under-represented 
with only 12 patients (3.6%). A better median PFS and 
OS were registered in patients with low SII at baseline 
that remained low at week 6 (18.7 and 49.4 months, 
respectively) (Table 3). Figure 2 shows the PFS and OS 
according to these four groups.
Table 1: Patients’ characteristics (n = 335)
No (%)
Median age, years (range) 63 (27–88)
Gender
   Males 238 (71.0)
   Females 97 (29.0)
ECOG Performance status
   0 197 (59.2)
   1 111 (33.3)
   ≥ 2 25 (7.5)
   missing 2
Histotype 
   Clear cell carcinoma 315 (94.0)
   Papillary 14 (4.2)
   Others 6 (1.8)
MSKCC score
   Good 98 (29.2)
   Intermediate 199 (59.4)
   Poor 38 (11.3)
IMDC score
   Good 117 (35.0)
   Intermediate 176 (52.5)
   Poor 42 (12.5)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan Kettering Cancer Center; IMDC, 
International Metastatic Renal Cell Carcinoma Database Consortium.
Figure 1: Progression-free survival (PFS) and overall survival (OS) according baseline SII. (A) Kaplan-Meier plots 
illustrating PFS according to baseline SII . (B) Kaplan-Meier plots illustrating OS according to baseline SII.
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DISCUSSION
The link between inflammation and cancer has been 
widely investigated in the last decades. Immune cells play a 
predominant role in the inflammatory process leading to the 
production of cytokines and chemokines that promote tumor 
growth, angiogenesis and metastasis [7]. Consequently, 
the complex balance between inflammatory cells and 
substances produced by inflammation may influence 
the type of cells detectable in the peripheral circulation. 
Platelets can induce circulating tumor cell epithelial-
mesenchymal transition and promote extravasation of 
tumor cells [15, 16]. Neutrophils can promote adhesion 
and tumoral seeding through the secretion of circulating 
growth factors [17, 18]. Lymphocytes display a significant 
antitumoral role by inducing cytotoxic cell death and 
Table 2: Univariate analysis for progression-free survival and overall survival 
Progression-free survival Overall survival











Overall 335 260 14.2 (12.1–17.2) - 193 32.7 (27.1–36.4) -
Age
   < 63 years 157 123 14.4 (10.8–18.7) 1.00 83 34.5 (29.1–50.1) 1.00
   ≥ 63 years 178 137 14.2 (10.4–17.2) 1.12 (0.88–1.43) 0.353 110 27.1 (20.3–35.7) 1.31 (0.99–1.75) 0.061
ECOG PS
   0–1 309 236 14.9 (13.3–18.4) 1.00 171 33.9 (29.1–40.6) 1.00
   2 25 24 3.0 (2.4–5.6) 3.63 (2.37–5.57) < 0.0001 22 6.5 (2.7–9.6) 4.50 (2.86–7.09) < 0.0001
Histotype
   Clear cell 315 243 14.3 (12.4–17.4) 1.00 179 33.6 (27.8–37.3) 1.00
   Papillary 14 11 7.1 (3.9–31.5) 1.36 (0.74–2.49) 0.321 9 13.3 (4.5-nr) 1.58 (0.81–3.10) 0.180
   Other 6 6 10.4 (1.1–22.6) 2.00 (0.89–4.51) 0.094 5 12.4 (1.7-nr) 1.90 (0.78–4.63) 0.159
MSKCC score
   Good 98 70 21.4 (17.7–27.5) 1.00 35 63.9 (44.5–75.2) 1.00
   Intermediate 199 161 12.1 (9.2–15.8) 1.48 (1.12–1.97) 0.006 134 27.1 (19.5–32.8) 2.44 (1.68–3.55) < 0.0001
   Poor 38 29 5.7 (3.9–8.3) 2.00 (1.29–3.09) 0.002 24 8.7 (5.4–25.1) 4.04 (2.39–6.82) < 0.0001
Good 98 70 21.4 (17.7–27.5) 1.00 35 63.9 (44.5–75.2) 1.00
Intermediate+Poor 237 190 10.6 (8.2–13.4) 1.55 (1.17–2.03) 0.002 158 23.8 (16.8–28.1) 2.59 (1.79–3.74) < 0.0001
IMDC score
   Good 117 84 21.4 (17.2–26.5) 1.00 48 56.6 (38.6–75.2) 1.00
   Intermediate 176 139 13.3 (9.2–17.4) 1.43 (1.09–1.87) 0.010 109 29.4 (24.0–36.0) 1.99 (1.41–2.80) < 0.0001
   Poor 42 37 4.0 (2.7–5.2) 5.09 (3.39–7.66) < 0.0001 36 5.3 (3.7–8.0) 11.12 (6.95–17.80) < 0.0001
Good 117 84 21.4 (17.2–26.5) 1.00 48 56.6 (38.6–75.2) 1.00
Intermediate+Poor 218 176 9.4 (7.5–12.4) 1.65 (1.27–2.15) 0.0002 145 23.7 (14.6–28.1) 2.42 (1.74–3.36) < 0.0001
SII baseline
   < 730 209 153 18.7 (14.7–22.8) 1.00 99  43.6 (35.3–52.1) 1.00
   ≥ 730 126 107 6.3 (5.5–8.9) 1.84 (1.43–2.36) < 0.0001 94 13.5 (9.8–18.5) 2.36 (1.78–3.14) < 0.0001
Abbreviations: CI, Confidence Interval; ECOG, Eastern Cooperative Oncology Group; HR, Hazard Ratio; IMDC, International Metastatic 
Renal Cell Carcinoma Database Consortium; MSKCC, Memorial Sloan Kettering Cancer Center; n., number; OS, Overall Survival; PFS, 
Progression Free Survival; pts, patients; PS, Performance Status, SII, Systemic Immune Inflammation Index.
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inhibiting tumor cell proliferation and migration, instituting 
the host’s immune response to cancer [19–20]. Therefore, 
inflammation deeply influences cancer microenvironment 
that supports cancer progression.
Many studies evaluated the role of prognostic 
scores based on peripheral inflammation cells in several 
tumors, in particular in RCC. Neutrophil-lymphocyte 
ratio is probably the most tested prognostic index and 
was associated with prognosis in several tumors such 
as breast, lung, pancreatic, colorectal, gastric, urothelial 
and also kidney cancers [13, 21–22]. Lymphopenia in 
preoperative blood count was also associated with poor 
prognosis in patients with RCC [23], and in elderly 
patients with RCC treated with sunitinib [24]. Platelets 
were also associated with prognosis in RCC [25, 26]. SII 
combines these three parameters and has been already 
significantly associated with prognosis in hepatocellular 
carcinoma and in colorectal cancer [14, 27]. Because SII 
evaluates parameters also included in the IMDC model 
such as neutrophil and platelets counts, we investigated 
the characteristics and the prognosis of 335 RCC patients 
evaluating for the first time the prognostic power of 
SII in this patient population. Our study presents some 
limitations relating to the retrospective nature of the 
analysis, and the sample size, however for the first time we 
demonstrated that SII at baseline and its changes at week 6 
are independent predictive and prognostic factors for 
these RCC patients underwent first-line sunitinib (Table 3, 
Figure 2). Interestingly, the improvement of SII value at 
week 6 (from ≥ 730 to < 730) was associated with a better 
prognosis (Table 3), as a possible effect of sunitinib in the 
counts of peripheral blood cells secondary to a reduction 
of inflammation processes. The low-high SII group was 
under-represented with only 12 patients (3.6%), so no firm 
conclusion can be drawn on these patients. In other series, 
which analyzed changes on neutrophil to lymphocyte 
ratio the percentage with low-high group was between 
0.8 to 4.8% [8, 21], so the conversion from good to bad 
group of systemic inflammatory markers after one cycle is 
confirmed to be uncommon. In clinical practice, a baseline 
SII value ≥ 730 decreasing at week 6 (after the first cycle 
of sunitinib) to value < 730, may encourage the physician 
to continue the treatment. In addition, we also saw a 
correlation between baseline and 6-week SII with clinical 
response/progression. Therefore, the integrated use of SII 
and imaging tools might lead to a significant improvement 
in therapeutic monitoring of patients with RCC, even if 
prospective study are needed to investigate this hypothesis. 
Figure 2: Progression-free survival (PFS) and overall survival (OS) according to SII risk group. (A) Kaplan-Meier plots 
illustrating PFS according SII risk group. (B) Kaplan-Meier plots illustrating OS according to SII risk group.
Table 3: Change in systemic immune-inflammation index and clinical outcome













Low Low 197 18.7 (14.6–22.9) 1.00 49.4 (35.3–56.6) 1.00
Low High 12 19.7 (4.3–25.2) 1.44 (0.76–2.74) 0.271 36.0 (5.3–41.8) 1.93 (0.93–4.00) 0.075
High Low 80 9.2 (6.2–10.6) 1.72 (1.29–2.31)  0.0004 18.2 (13.1–27.1) 2.12 (1.52–2.95) < 0.0001
High High 44 4.0 (2.6–5.8) 2.12 (1.48–3.04) < 0.0001 9.4 (6.1–13.5) 3.17 (2.14–4.69) < 0.0001
Abbreviations: CI, confidence interval; HR, hazard ratio; n., number; PFS, progression-free survival; pts, patients; OS, 
overall survival; SII, systemic immune-inflammation index.
*Two patients were excluded of the analysis since they had a progression or death within the 6-week (landmark analysis).
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The use of validated prognostic indices is essential 
in clinical practice to better make correct decisions on 
the use of high-cost drugs and to potentially reduce the 
impact of toxicities especially in more frail patients. In 
advanced RCC, the IMCD model is currently accepted 
as the reference in prognostic stratification and replaced 
in clinical practice the MSKCC criteria. In this paper 
we want to purpose SII as a new tool to define outcome 
stratification in renal cancer patients. SII changes could be 
able to predict response to treatment and clinical outcome 
of these patients, giving a potential simple tool to monitor 
the effect of treatment on the clinical outcome of these 
patients. In addition, this inflammatory index is of special 
interest in RCC, which is an immune-responsive disease, 
and new immune-oncologic agents, like checkpoint 
inhibitors are in active development as agents for the 
treatment of systemic disease [28].
In conclusion, to our knowledge, this is the first 
study to demonstrate that SII and its changes during 
treatment with sunitinib, could represent an independent 
prognostic factor for patients with advanced RCC 
undergoing first-line treatment with sunitinib. Validation 
in a larger prospective data set is warranted. 
MATERIALS AND METHODS
Study patients
We retrospectively evaluated 335 patients with 
advanced renal cell carcinoma treated with sunitinib as 
first-line therapy between January 2006 and December 
2014 in our seven Institutions. The SII is a new index 
based on platelets, neutrophils and lymphocytes counts 
and was defined as follows: SII = P × N/L. The X-tile 3.6.1 
software (Yale University, New Haven, CT) was used for 
bioinformatic analysis of the baseline data to determine 
the cutoff value of SII.
The accuracy of all of the clinical, pathologic, and 
radiologic data obtained from the institutional databases 
was validated for each patient by an independent observer 
using the medical records. Data were collected into 
electronic data files by the local physicians and checked at 
the central data management. Patients with history of other 
treatments before sunitinib were not considered for the 
analysis. Sunitinib was administered according to clinical 
practice at the initial dose of 50 mg day with the standard 
schedule 4 weeks on, 2 weeks off. Dose adjustments were 
adopted as needed case by case according to toxicities or 
other relevant medical conditions. Patients were treated 
until disease progression or unacceptable toxicity occurred. 
Toxicities were evaluated and registered according to 
the National Cancer Institute Common Toxicity Criteria 
version 3.0 (NCI-CTC v.3.0). The response to treatment 
was assessed according to the Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria on the basis of 
the validated reports obtained from the medical records. 
According to the clinical practice, patients were evaluated 
at each cycle for possible toxicities with clinical visit 
and full blood examinations, including a complete blood 
count, whereas a computed tomographic scan was done 
at baseline and repeated every 3 months during treatment 
with sunitinib. This study was carried out in accordance 
with the approval of the ethical committees. 
Statistical analysis 
Data were summarized by frequency for categorical 
variables and by median and range for continuous 
variables. Association between categorical variables was 
assessed using the Chi-square or Fisher’s exact test, when 
appropriate. Differences were considered statistically 
significant when p < 0.05. PFS was calculated from the 
start of first-line treatment until disease progression or last 
follow-up. OS was calculated from the start of first-line 
treatment until death or last follow-up. The Kaplan–Meier 
method was used to estimate PFS and OS. The logrank test 
and Cox proportional hazard regression were used to test 
for differences between groups. After univariate analysis, 
a multivariate analysis was carried out by Cox regression 
model. Estimated hazard ratios (HR), their 95% confidence 
intervals (95% CI), and p values were calculated from the 
Cox proportional hazard regression models.
The impact of change on survival outcomes was 
evaluated by the landmark analysis at 6-weeks. For this 
analysis, patients with early disease progression/death or 
patients lost to follow-up before the landmark time were 
excluded. All statistical analyses were carried out with SAS 
statistical software, version 9.4 (SAS Institute, Cary, NC).
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